Data on HIV-1 incidence following programmatic pre-exposure prophylaxis (PrEP) uptake by men who have sex with men (MSM) in sub-Saharan Africa is not available. We assessed PrEP uptake and adherence, and HIV-1 incidence, in at-risk MSM with access to PrEP in coastal Kenya.
Since June 2017, at-risk MSM followed at monthly visits were offered daily PrEP with adherence and risk reduction counselling. At each visit, we assessed PrEP adherence, intention to continue, and HIV-1 status using rapid antibody tests. If symptoms of acute HIV-1 (e.g. fever) or risk criteria (e.g. receptive anal sex,) were met, X-pert RNA Qual testing was done. We determined tenofovir-diphosphate (TFV-DP) concentrations in dried blood spots 6-12 months after PrEP initiation, and tenofovir (TFV) concentrations and genotypic drug resistance in plasma samples when HIV-1 was detected. HIV-1 incidence was assessed as per reported PrEP use, and population-averaged multivariable Poisson regression with robust standard errors was used to identify predictors of HIV-1 acquisition.
Of 167 at-risk MSM, 162 (94.9%) were eligible for PrEP, 131 (80.9%) started it, and 57 (43.5%) reported PrEP use at study censoring, for a median follow-up time of 21.2 (interquartile range: 10.2–22.1) months. Nine MSM acquired HIV-1 [incidence rate: 3.9 (95% confidence interval (CI), 2.0–7.4) per 100 person-years (PY)]. Of these, 5 MSM reported PrEP use at the time of HIV-1 acquisition [incidence rate: 3.7 (95% CI, 1.5–8.8) per 100 PY] and 4 MSM had stopped or had never started PrEP [incidence rate: 4.2 (95% CI, 1.6–11.1) per 100 PY; figure]. Among 75 (57.3%) MSM who reported PrEP use, 11 (14.7%) had protective TFV-DP levels of ≥700 fmol/punch (≥4 tablets a week). Among the 5 MSM who acquired HIV-1 while reporting to take PrEP, only one had detectable but low TFV levels in plasma (66.0 ng/mL) and none had genotypic HIV-1 resistance. In multivariable analysis, no factors were significantly associated with HIV-1 acquisition.
HIV-1 incidence among at-risk MSM with access to programmatic PrEP was high and did not differ by reported PrEP use. Only one in seven MSM taking PrEP had protective tenofovir levels, and a substantial proportion of MSM stopped taking PrEP despite frequent risk reduction counselling. Strengthened PrEP adherence support is required among MSM in Kenya.